Re: Effect of dutasteride on the risk of prostate cancer

Re: Effect of dutasteride on the risk of prostate cancer

Bibliografski detalji
Glavni autori:	Sooriakumaran, P, Tewari, A
Format:	Journal article
Jezik:	English
Izdano:	2010

Slični predmeti

Words of wisdom. Re: Effect of dutasteride on the risk of prostate cancer. Andriole GL, Bostwick DG, Brawley OW, et al.
od: Sooriakumaran, P, i dr.
Izdano: (2010)

Endorectal MRI: Use in Prostate Cancer
od: Srivastava, A, i dr.
Izdano: (2012)

Predictive models for worsening prognosis in potential candidates for active surveillance of presumed low-risk prostate cancer.
od: Sooriakumaran, P, i dr.
Izdano: (2012)

Prostate volume and its correlation with histopathological outcomes in prostate cancer.
od: Sooriakumaran, P, i dr.
Izdano: (2011)

The risks and benefits of cyclo-oxygenase-2 inhibitors in prostate cancer: a review.
od: Sooriakumaran, P, i dr.
Izdano: (2005)

Smarter screening for prostate cancer: for the few, not the many? A stratified approach based on baseline risk.
od: Sooriakumaran, P
Izdano: (2011)

Management of prostate cancer. Part 1: chemoprevention.
od: Sooriakumaran, P
Izdano: (2006)

RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
od: Brenna, J, i dr.
Izdano: (2014)

Does the introduction of prostate multiparametric MRI into active surveillance of localised prostate cancer improve patient re-classification?
od: Bryant, R, i dr.
Izdano: (2018)

Future prospects: who is the patient who still dies of prostate cancer following local treatment of high-risk prostate cancer? Can we prolong their lives using modern treatment approaches?
od: Ayres, B, i dr.
Izdano: (2013)

Management of prostate cancer. Part 3: metastatic disease.
od: Shah, J, i dr.
Izdano: (2006)

Angiogenesis and the tumour hypoxia response in prostate cancer: a review.
od: Sooriakumaran, P, i dr.
Izdano: (2005)

Gleason scoring varies among pathologists and this affects clinical risk in patients with prostate cancer.
od: Sooriakumaran, P, i dr.
Izdano: (2005)

Minimally invasive surgical modalities in the management of localized prostate cancer.
od: Jamal, K, i dr.
Izdano: (2008)

Metformin and prostate cancer: a new role for an old drug
od: Whitburn, J, i dr.
Izdano: (2017)

Clinicopathological strategies to identify contralateral prostate cancer involvement in potential candidates for focal therapy.
od: Grover, S, i dr.
Izdano: (2010)

Management of prostate cancer. Part 2: localized and locally advanced disease.
od: Sooriakumaran, P, i dr.
Izdano: (2006)

Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy.
od: Tewari, A, i dr.
Izdano: (2012)

Familial risk of prostate cancer in Iceland.
od: Eldon, B, i dr.
Izdano: (2003)

Management of low-risk prostate cancer.
od: Gardiner, R, i dr.
Izdano: (2008)

Vasectomy and the Risk of Prostate Cancer COMMENTS
od: Goldacre, M
Izdano: (2008)

Reply from authors re: Anders Bjartell "a robot saved my life": Is it a myth? Eur Urol 2012;62:775-6: The debate on the oncologic safety of robotics in prostate cancer is over: Time to move on
od: Sooriakumaran, P, i dr.
Izdano: (2012)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
od: Vickers, A, i dr.
Izdano: (2010)

COX-2 inhibition: a possible role in the management of prostate cancer?
od: Sooriakumaran, P, i dr.
Izdano: (2007)

Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.
od: Shui, I, i dr.
Izdano: (2014)

Prostate cancer (PCa) risk variants and risk of fatal PCa in the national cancer institute breast and prostate cancer cohort consortium
od: Shui, I, i dr.
Izdano: (2014)

Apples and oranges: comparison of treatment methods for prostate cancer using biochemical recurrence as an endpoint.
od: Sooriakumaran, P, i dr.
Izdano: (2012)

Epidemiology of metabolite profile and prostate cancer risk
od: Schmidt, J
Izdano: (2017)

Radical therapy may reduce mortality in men with metastatic prostate cancer
od: Sooriakumaran, P, i dr.
Izdano: (2014)

A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer.
od: Sooriakumaran, P, i dr.
Izdano: (2009)

Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes.
od: Sooriakumaran, P, i dr.
Izdano: (2014)

Smoking and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition.
od: Rohrmann, S, i dr.
Izdano: (2013)

Smoking and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition
od: Rohrmann, S, i dr.
Izdano: (2013)

Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.
od: Chen, Y, i dr.
Izdano: (2007)

n-3 Fatty acids and prostate cancer risk.
od: Brasky, T, i dr.
Izdano: (2012)

Identification of new genetic risk factors for prostate cancer.
od: Guy, M, i dr.
Izdano: (2009)

Models to predict positive prostate biopsies using the Tyrol screening study.
od: Sooriakumaran, P, i dr.
Izdano: (2011)

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio.
od: Aus, G, i dr.
Izdano: (2004)

Prostate cancer /
od: 375298 Cramer, Scott D.
Izdano: (2007)

Plasma selenium concentration and prostate cancer risk Reply
od: Allen, N, i dr.
Izdano: (2009)